ReviewDrug design, development and therapy2020
Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration.
Review in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Efficacy of growth factor gene-modified stem cells for motor function after spinal cord injury in rodents: a systematic review and meta‑analysis.Neurosurgical review · 2024Pooled it
- Click-crosslinked nanogels integrated into 3D stem cell spheroids enhance regenerative function for swallowing muscle repair.Biomaterials · 2026Article
- Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Tissue-engineered cardiac patches enriched with IGF1 modified mRNA alleviate myocardial infarction by enhancing cell survival and angiogenesis.Materials today. Bio · 2026Article
- A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous UMC119-06 in Patients with Acute Ischemic Stroke.International journal of medical sciences · 2026Article
- Cytoprotective and Immunomodulatory Properties of Mesenchymal Stem Cell Secretome and Its Effect on Organotypic Hippocampal Cultures in Mouse Model of Temporal Lobe Epilepsy.International journal of molecular sciences · 2025Article
- Article
- Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies.Signal transduction and targeted therapy · 2025Review
- Immediate Oncoplastic Breast Reconstruction with Fat Grafting: Preliminary Radiological, Aesthetic, and Patient Satisfaction Outcomes.Aesthetic plastic surgery · 2025Article
- Mesenchymal stromal cell therapy: Progress to date and future outlook.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Therapeutic potential of mesenchymal stem cells in cisplatin-induced acute kidney injury via ASK-1/TXNIP pathway modulation.Archives of medical science : AMS · 2025Article
- Manipulated mesenchymal stem cell therapy in the treatment of Parkinson's disease.Stem cell research & therapy · 2024Review
- Effects of Late-Passage Small Umbilical Cord-Derived Fast Proliferating Cells on Tenocytes from Degenerative Rotator Cuff Tears under an Interleukin 1β-Induced Tendinopathic Environment.Tissue engineering and regenerative medicine · 2024Article
- Therapeutic Applications of Engineered Mesenchymal Stromal Cells for Enhanced Angiogenesis in Cardiac and Cerebral Ischemia.Stem cell reviews and reports · 2024Review
- Effects, methods and limits of the cryopreservation on mesenchymal stem cells.Stem cell research & therapy · 2024Review
- Effects of Human Neural Stem Cells Overexpressing Neuroligin and Neurexin in a Spinal Cord Injury Model.International journal of molecular sciences · 2024Article
- Wharton's jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury.World journal of stem cells · 2024Review
- Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions.Signal transduction and targeted therapy · 2024Review
- Immunomodulatory performance of GMP-compliant, clinical-grade mesenchymal stromal cells from four different sources.Heliyon · 2024Article
- Human retinal secretome: A cross-link between mesenchymal and retinal cells.World journal of stem cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There have been marked changes in the field of stem cell therapeutics in recent years, with many clinical trials having been conducted to date in an effort to treat myriad diseases. Mesenchymal stem cells (MSCs) are the cell type most frequently utilized in stem cell therapeutic and tissue regenerative strategies, and have been used with excellent safety to date. Unfortunately, these MSCs have limited ability to engraft and survive, reducing their clinical utility. MSCs are able to secrete growth factors that can support the regeneration of tissues, and engineering MSCs to express such growth factors can improve their survival, proliferation, differentiation, and tissue reconstructing abilities. As such, it is likely that such genetically modified MSCs may represent the next stage of regenerative therapy. Indeed, increasing volumes of preclinical research suggests that such modified MSCs expressing growth factors can effectively treat many forms of tissue damage. In the present review, we survey recent approaches to producing and utilizing growth factor gene-modified MSCs in the context of tissue repair and discuss its prospects for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.